NASDAQ : NBP
NovaBridge Biosciences — Key statistics
Healthcare · Biotechnology · United States
Last price 1.195 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 138.62M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 138.62M |
| Enterprise Value | -47.77M |
Dates
| Measure | Value |
|---|
| Earnings Date | Aug 20, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | n/a |
| Shares Outstanding | 116.00M |
| Shares Change (YoY) | +38.28% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 7.55% |
| Owned by Institutions (%) | 16.16% |
| Float | 64.44M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.69 |
| P/TBV Ratio | 0.69 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 7.64 |
| Quick Ratio | 7.58 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -59.10% |
| Return on Assets (ROA) | -34.98% |
| Return on Invested Capital (ROIC) | -833.39% |
| Return on Capital Employed (ROCE) | -59.64% |
| Weighted Average Cost of Capital (WACC) | 12.62% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$3.92M |
| Employee Count | 30 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.60 |
| 52-Week Price Change | -74.19% |
| 50-Day Moving Average | 1.52 |
| 200-Day Moving Average | 2.19 |
| Relative Strength Index (RSI) | 35.33 |
| Average Volume (20 Days) | 451,159 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 3.70M |
| Short Previous Month | 3.28M |
| Short % of Shares Out | 7.07% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 5.86 |
Incomestatement
| Measure | Value |
|---|
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -122.63M |
| Pretax Income | -117.55M |
| Net Income | -117.55M |
| EBITDA | -122.53M |
| EBIT | -122.63M |
| Earnings Per Share (EPS) | -$1.04 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 190.85M |
| Total Debt | 4.46M |
| Net Cash | 186.39M |
| Net Cash Per Share | $1.61 |
| Equity (Book Value) | 201.10M |
| Book Value Per Share | 1.73 |
| Working Capital | 172.08M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -45.68M |
| Capital Expenditures | -990,000 |
| Depreciation & Amortization | 107,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -46.67M |
| FCF Per Share | -$0.40 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -38.28% |
| Shareholder Yield | -38.28% |
| Earnings Yield | -87.21% |
| FCF Yield | -33.67% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $9.00 |
| Price Target Difference | 653.14% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |